Cargando…

Clinical development plan for regenerative therapy in heart failure

Detalles Bibliográficos
Autores principales:	Terzic, Andre, Behfar, Atta, Filippatos, Gerasimos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2016
Materias:	Focus Issue on Cardiac Regeneration
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215378/ https://www.ncbi.nlm.nih.gov/pubmed/26800140 http://dx.doi.org/10.1002/ejhf.479

Ejemplares similares

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design
por: Bartunek, Jozef, et al.
Publicado: (2015)

Regenerative heart failure therapy headed for optimization
por: Terzic, Andre, et al.
Publicado: (2014)

Screening for regenerative therapy responders in heart failure
por: Yamada, Satsuki, et al.
Publicado: (2021)

Mass Customized Outlook for Regenerative Heart Failure Care
por: Yamada, Satsuki, et al.
Publicado: (2021)

Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy
por: Yamada, Satsuki, et al.
Publicado: (2015)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy
por: Yamada, Satsuki, et al.
Publicado: (2019)

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)
por: Metra, Marco, et al.
Publicado: (2022)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Cardiopoietic stem cell therapy in ischaemic heart failure: long‐term clinical outcomes
por: Bartunek, Jozef, et al.
Publicado: (2020)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Diagnosis of acute heart failure in CT pulmonary angiography: feasibility and accuracy
por: Vittoria de Martini, Ilaria, et al.
Publicado: (2022)

Endpoints in stem cell trials in ischemic heart failure
por: Banovic, Marko, et al.
Publicado: (2015)

Right sided heart failure secondary to hypereosinophilic cardiomyopathy – clinical manifestation and diagnostic pathway
por: Han, Jennie, et al.
Publicado: (2020)

Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure
por: Soppa, Gopal K.R., et al.
Publicado: (2008)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Genomic chart guiding embryonic stem cell cardiopoiesis
por: Faustino, Randolph S, et al.
Publicado: (2008)

Integrate and boost: bioscaffolds nurture the cardiac regenerative paradigm
por: Bartunek, Jozef, et al.
Publicado: (2015)

Significance of myocardial tenascin‐C expression in left ventricular remodelling and long‐term outcome in patients with dilated cardiomyopathy
por: Yokokawa, Tetsuro, et al.
Publicado: (2016)

Molecular and structural transition mechanisms in long‐term volume overload
por: Mohamed, Belal A., et al.
Publicado: (2015)

Bmi1, medulloblastoma and regenerative therapy
Publicado: (2013)

Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome
por: Arrell, D. Kent, et al.
Publicado: (2020)

Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure
por: Caravita, Sergio, et al.
Publicado: (2022)

Hyaline cartilage differentiation of fibroblasts in regeneration and regenerative medicine
por: Yu, Ling, et al.
Publicado: (2022)

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021)

Imaging technologies for monitoring the safety, efficacy and mechanisms of action of cell-based regenerative medicine therapies in models of kidney disease
por: Sharkey, Jack, et al.
Publicado: (2016)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Transcriptional response to Wnt activation regulates the regenerative capacity of the mammalian cochlea
por: Samarajeewa, Anshula, et al.
Publicado: (2018)

Cardiac Contusion Complicated by Heart Failure in a Young Athlete
por: Pabba, Krishna, et al.
Publicado: (2022)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Cardiac resynchronization therapy is associated with improvement in clinical outcomes in Indian heart failure patients: Results of a large, long-term observational study
por: Naik, Ajay, et al.
Publicado: (2018)

The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
por: Harouki, Najah, et al.
Publicado: (2017)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

An Unexpected Cause of Heart Failure in a Young Woman With Treated Lymphoma
por: Poon, Jessica, et al.
Publicado: (2021)

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Hemodynamic Assessment of Dual Obstructive Left Ventricular Assist Device Lesions
por: Kassi, Mahwash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kdghe33voj6l3dcv0vuajv0rh0